Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Histone H2B clustered histone 6 (H2BC6)
- Target
- H2BC6
- Molecular classification
- Histone protein, Nucleosomal protein, Chromatin structural protein
01
Overview
Histone H2B clustered histone 6 (H2BC6) is one of several H2B histone variants found in humans. This protein is a core component of the nucleosome structure, participating in the compaction and organization of chromosomal DNA by forming an octamer with histones H2A, H3, and H4. H2BC6 is involved in regulating transcription, DNA replication, genome integrity, and DNA repair by contributing to the structural foundation of chromatin and by undergoing various post-translational modifications such as acetylation and ubiquitination, which modulate its function and interactions. While H2B proteins, including H2BC6, play central roles in epigenetic cellular regulation, they are not typical drug targets, although changes in their modification pattern can serve as readouts for disease or cellular state.
- Other names
- H2B clustered histone 6HIST1H2BEH2BC10H2BC4H2BC7H2BC8dJ221C16.8H2BFHH2B/hH2B.h
02
Mechanism of action
Not applicable (no drugs are known to directly target H2BC6)
03
Biological functions
Chromatin compaction and nucleosome formationRegulation of gene transcription (via nucleosome rearrangement and post-translational modification)DNA replication and DNA damage repairMaintenance of genome integrityRegulation through post-translational modifications (e.g., acetylation, ubiquitination)
04
Disease associations
Cancer and other diseases with epigenetic dysregulation (altered histone modification has been implicated, but H2BC6 itself is not usually a direct disease driver)Genome instability syndromesEpigenetic regulation in differentiation and development
05
Safety considerations
Targeting histones (as a drug target or biomarker) carries risk of broad disruption of gene expression, genome instability, and cytotoxicityTherapeutic modulation of histone modifications is under study but faces significant safety challenges due to systemic effects.
06
Interacting drugs
None specifically reported (general histone modifying agents, e.g., histone deacetylase inhibitors, can indirectly affect H2B proteins, but H2BC6 is not a direct pharmacological target)
07
Biomarkers
None specific (histone modifications, such as H2B ubiquitination or acetylation, can be biomarkers for transcriptional activity or epigenetic state, but not H2BC6 isoform itself)
Beyond the preview
Go deeper on Histone H2B clustered histone 6 (H2BC6).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Histone H2B clustered histone 6 (H2BC6).